![]() |
Volumn 19, Issue 3, 2011, Pages 1242-1255
|
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship
|
Author keywords
Asthma; COPD; DOA; IKK 2; Inhaled approach; Inhibitors; Potent; Selective
|
Indexed keywords
1 (3 CHLORO 4 HYDROXYPHENYL) 8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
1 (4 CHLORO 3 HYDROXYPHENYL) 8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
1 (4 {[3 CARBAMOYL 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]CARBAMOYL} 5 CHLOROPYRIDIN 2 YL) 4 [(1 METHYL 1H PYRAZOL 4 YL)METHYL]PIPERAZINE 2 CARBOXYLIC ACID;
4 (4 {[3 CARBAMOYL 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]CARBAMOYL} 5 CHLOROPYRIDIN 2 YL) 1 [(1 METHYL 1H PYRAZOL 4 YL)METHYL]PIPERAZINE 2 CARBOXYLIC ACID;
8 (5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINAMIDO) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 ({5 CHLORO 2 [4 ({1 [2 (DIMETHYLAMINO) 2 OXOETHYL] 1H PYRAZOL 4 YL}METHYL)PIPERAZIN 1 YL]ISONICOTINOYL}AMINO) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 ({5 CHLORO 2 [4 ({1 [2 (ISOPROPYLAMINO) 2 OXOETHYL] 1H PYRAZOL 4 YL}METHYL)PIPERAZIN 1 YL]ISONICOTINOYL}AMINO) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 ({5 CHLORO 2 [4 ({1 [3 (2 METHOXYETHOXY)PROPYL] 1H PYRAZOL 4 YL}METHYL)PIPERAZIN 1 YL]ISONICOTINOYL}AMINO) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 ({5 CHLORO 2 [4 ({1 [3 (DIMETHYLAMINO)PROPYL] 1H PYRAZOL 4 YL}METHYL)PIPERAZIN 1 YL]ISONICOTINOYL}AMINO) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 [(5 CHLORO 2 {(3) 3 METHYL 4 [(1 METHYL 1H PYRAZOL 4 YL)METHYL]PIPERAZIN 1 YL}ISONICOTINOYL)AMINO] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 [(5 CHLORO 2 {4 [(1 METHYL 1H PYRAZOL 4 YL)METHYL]PIPERAZIN 1 YL}ISONICOTINOYL)AMINO] 1 (3 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 [(5 CHLORO 2 {4 [(1 METHYL 1H PYRAZOL 4 YL)METHYL]PIPERAZIN 1 YL}ISONICOTINOYL)AMINO] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 [(5 CHLORO 2 {4 [(1 {2 [(2 METHOXYETHYL)AMINO] 2 OXOETHYL} 1H PYRAZOL 4 YL)METHYL]PIPERAZIN 1 YL}ISONICOTINOYL)AMINO] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G] INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL] AMINO} 1 (3 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (3 HYDROXYPHENYL) 4,5 DIHYDRO 1H BENZO[G] INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (3,4 DIFLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 HYDROXYPHENYL) 4,5 DIHYDRO 1H BENZO[G] INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 METHOXYPHENYL) 4,5 DIHYDRO 1H BENZO[G] INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 {[1 (2 CYANOETHYL) 1H PYRAZOL 4 YL]METHYL}PIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 {[1 (2 {[2 (METHYLTHIO)ETHYL] AMINO} 2 OXOETHYL) 1H PYRAZOL 4 YL]METHYL}PIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 {[1 (3 HYDROXYPROPYL) 1H PYRAZOL 4 YL]METHYL}PIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
8 {[5 CHLORO 2 (4 {[1 (3 METHOXYPROPYL) 1HPYRAZOL 4 YL]METHYL}PIPERAZIN 1 YL)ISONICOTINOYL]AMINO} 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE;
AMIDE;
AMINOPYRIDINE DERIVATIVE;
ETHYL 3 [4 ({4 [4 ({[3 (AMINOCARBONYL) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]AMINO}CARBONYL) 5 CHLOROPYRIDIN 2 YL]PIPERAZIN 1 YL}METHYL) 1H PYRAZOL 1 YL]PROPANOATE;
ETHYL [4 ({4 [4 ({[3 (AMINOCARBONYL) 1 (3 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]AMINO} CARBONYL) 5 CHLOROPYRIDIN 2 YL]PIPERAZIN 1 YL}METHYL) 1H PYRAZOL 1 YL]ACETATE;
ETHYL [4 ({4 [4 ({[3 (AMINOCARBONYL) 1 (4 FLUOROPHENYL)4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]AMINO}CARBONYL) 5 CHLOROPYRIDIN 2 YL]PIPERAZIN 1 YL}METHYL) 1H PYRAZOL 1 YL]ACETATE;
I KAPPA B KINASE INHIBITOR;
METHYL [4 ({4 [4 ({[3 (AMINOCARBONYL) 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOL 8 YL]AMINO}CARBONYL) 5 CHLOROPYRIDIN 2 YL]PIPERAZIN 1 YL}METHYL) 1H PYRAZOL 1 YL]ACETATE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ARTICLE;
ASTHMA;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CONTROLLED STUDY;
DRUG CLEARANCE;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
STRUCTURE ACTIVITY RELATION;
ADMINISTRATION, INHALATION;
AMINOPYRIDINES;
ASTHMA;
BINDING, COMPETITIVE;
DRUG DESIGN;
HEK293 CELLS;
HUMANS;
I-KAPPA B KINASE;
INDAZOLES;
ISONICOTINIC ACIDS;
MICROSOMES, LIVER;
MODELS, MOLECULAR;
MOLECULAR STRUCTURE;
MOLECULAR TARGETED THERAPY;
NIACINAMIDE;
PHENETHYLAMINES;
POTASSIUM CHANNEL BLOCKERS;
PROTEIN KINASE INHIBITORS;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
PYRAZOLES;
STRUCTURE-ACTIVITY RELATIONSHIP;
SULFONAMIDES;
|
EID: 79551496434
PISSN: 09680896
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmc.2010.12.027 Document Type: Article |
Times cited : (13)
|
References (42)
|